Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Prediabetes Market

Prediabetes Market Share

Report ID: GMI8874
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Prediabetes Market Share

The prediabetes industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.

Prediabetes Market Companies

Some of the eminent market participants operating in the prediabetes industry include:

Abbott Laboratories
AstraZeneca PLC
CH Boehringer Sohn AG & Co KG
Eli Lilly and Company
Glenmark Pharmaceuticals Limited
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Takeda Pharmaceutical Company Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Prediabetes industry size recorded USD 198.4 million in 2023 and will grow at a 6.9% CAGR between 2024 and 2032 owing to rise in obesity rates and sedentary lifestyles, emphasis on preventive healthcare measures and investments in screening programs.

The biguanides segment in the prediabetes industry will register USD 254.6 million by 2032, attributed to the effectiveness and widespread use of biguanides, such as metformin, as a first-line treatment for prediabetes.

North America prediabetes industry captured 40.7% revenue share in 2023, driven by high prevalence of prediabetes in the region, rising obesity rates, and sedentary lifestyles.

Prominent prediabetes firms are Abbott Laboratories, AstraZeneca PLC, CH Boehringer Sohn AG & Co KG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Takeda Pharmaceutical Company Limited, among others.